Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey.

Igho-Osagie, Ebuwa; Brzozowski, Kaylen; Jin, Harry; Brown, Jeffrey; Williams, Marissa Grifasi; Puenpatom, Amy

Igho-Osagie, Ebuwa; Brzozowski, Kaylen; Jin, Harry; Brown, Jeffrey; Williams, Marissa Grifasi; Puenpatom, Amy.

Affiliation

Igho-Osagie E; Merck & Co Inc, Rahway, New Jersey.
Brzozowski K; TriNetX, Cambridge, Massachusetts. Electronic address: Kaylen.Brzozowski@TriNetX.com.
Jin H; TriNetX, Cambridge, Massachusetts.
Brown J; TriNetX, Cambridge, Massachusetts.
Williams MG; Merck & Co Inc, Rahway, New Jersey.
Puenpatom A; Merck & Co Inc, Rahway, New Jersey.

Clin Ther ; 45(5): 390-399.e4, 2023 05.

Article in En | MEDLINE | ID: mdl-37032225

Subject(s)

COVID-19; HIV Infections; Adult; Humans; United States/epidemiology; Ritonavir/therapeutic use; Nutrition Surveys; Prevalence; Cytochrome P-450 CYP3A; COVID-19/epidemiology; COVID-19/complications; COVID-19 Drug Treatment; Drug Interactions; HIV Infections/drug therapy

Key words

COVID-19; NHANES; drug interaction; nirmatrelvir/ritonavir; polypharmacy; ritonavir

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: Clin Ther Year: 2023 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google